Biotechnology giant Amgen (AMGN) entered what it calls its “springboard year.” The company is facing a critical transition year with patent expirations and increasing biosimilar competition ...

Looking at the universe of stocks we cover at Dividend Channel, on 8/22/25, Amgen Inc (Symbol: AMGN), U.S. Physical Therapy, Inc. (Symbol: USPH), and Dynex Capital Inc (Symbol: DX) will all trade ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen ...

Amgen Inc (Symbol: AMGN) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $30.99B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a ...

This strategy not only helps shield us in a panic—it leverages market chaos for bigger gains (and a fatter income stream) ...

Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies looking to stay ahead of rivals, especially as biosimilar competition grows. The ...

Amgen and Novartis could feel the effects of tariffs in the short run. However, both companies should still be long-term winners thanks to their innovative abilities. Both healthcare leaders have ...

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.

THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend ...